Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royal Bank of Canada (TSX:RY)

163.45 +2.61 (+1.62%)
Streaming Delayed Price Updated: 3:05 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royal Bank of Canada

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Lyft And DoorDash Stocks Are Trading Higher Monday - Here's Why
RBC Capital analyst upgraded Lyft & DoorDash stocks, raising price targets. Improved execution, partnerships & growth potential driving confidence. 
Via Benzinga
Lyft And DoorDash Rise On Upgrades. Analyst Says They Should Partner Up.
Lyft stock and DoorDash gained Monday on an upgrade from RBC Capital. Analysts said the two companies could benefit by teaming up. 
Via Investor's Business Daily
RBC Capital Maintains Sector Perform Rating for GMS: Here's What You Need To Know
Via Benzinga
RBC Capital Maintains Outperform Rating for Gaming and Leisure Props: Here's What You Need To Know
Via Benzinga
Shift4 Payments: Analysts Highlight Growth Opportunities Despite Q4 Challenges
RBC Capital analyst maintained Shift4 Payments with Outperform rating and raised price target from $80 to $94. Q1 revenue projected at $279.6M. 
Via Benzinga
Preview: RBC Bearings's Earnings
Via Benzinga
Warrior Met Coal's Ballooning Development Costs Prompt Analysts To Rethink Projections
RBC analysts lower price target for Warrior Met Coal to $64 due to higher costs at Blue Creek mine. Capex expected to be $1B in 2024. 
Via Benzinga
Exposures Coal
What's Going On With Booking Holdings Stock After Earnings?
RBC Capital analyst Brad Erickson maintained Booking Holdings with an Outperform and raised the price target from $3550 to $3900, and Wedbush analyst Scott Devitt reiterated Booking Holdings with an... 
Via Benzinga
RBC Capital Maintains Sector Perform Rating for Bausch Health Companies: Here's What You Need To Know
Via Benzinga
Navigating Discover's Merger With Capital One: Analyst Highlights Opportunities And Challenges Ahead
RBC Capital Markets downgrades Discover Financial to Sector Perform with increased price target of $140. Merger with Capital One expected to be accretive and generate $2.7B in synergies. Analyst sees... 
Via Benzinga
Here's How Much You Would Have Made Owning RBC Bearings Stock In The Last 15 Years
Via Benzinga
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset... 
Via Benzinga
RBC Capital Maintains Sector Perform Rating for NMI Holdings: Here's What You Need To Know
Via Benzinga
RBC Illuminates Solar Sector, Launches Coverage For 4 Solar Equipment Leaders
RBC Capital Markets highlighted favorable public policy and declining costs within the solar industry and initiated coverage on several solar equipment suppliers, including First Solar, Enphase Energy,... 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
RBC Capital Maintains Outperform Rating for Datadog: Here's What You Need To Know
Via Benzinga
Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month
"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins... 
Via Benzinga
RBC Capital's Rating Upgrade Propels IGM Biosciences Into Immunology Limelight
IGM Biosciences' strategic shift to immunology with promising bispecific drug, imvotamab. RBC Capital upgraded stock to Outperform, anticipating $21 price target. Data expected in 2H 2024 validates its... 
Via Benzinga
RBC Capital Maintains Sector Perform Rating for Thomson Reuters: Here's What You Need To Know
Via Benzinga
RBC Capital Maintains Outperform Rating for Ensign Group: Here's What You Need To Know
Via Benzinga
Uber, Lyft Can Hitch A Ride Higher If Q4 Earnings Beat Wall Street Estimates
Uber reports on Wednesday, while Lyft Q4s are on Feb. 13. RBC has a sector perform rating on Lyft and an outperform rating on Uber. 
Via Benzinga
Topics Earnings
Exposures Financial
Capstone Copper Announces Multimillion-Dollar Financing To Support Its Chilean Expansion
Capstone Copper Corp. and Orion Mine Finance arranged a CA$375 million bought deal with RBC Capital Markets, expected to close on Feb. 8, 2024. 
Via Benzinga
RBC Capital Maintains Outperform Rating for Reinsurance Gr: Here's What You Need To Know
Via Benzinga
RBC Capital Maintains Sector Perform Rating for Bio-Techne: Here's What You Need To Know
Via Benzinga
RBC Capital Maintains Outperform Rating for Thermo Fisher Scientific: Here's What You Need To Know
Via Benzinga
What's In Store For Clorox This Earnings Season? Analyst Sees Issues With Trash Bags, Cat Litter & More
Clorox faces challenges in key product categories like trash bags and cat litter, hindering recovery from the 2023 cyber-attack, according to RBC analyst Nik Modi. 
Via Benzinga
'We Stay The Course On Meta And Amazon': Analysts Preview Tech Earnings
RBC is looking for acceleration in Amazon's AWS cloud offering and expects increasing adoption of Advantage+ to be a key driver of Meta. 
Via Benzinga
Foresight to Participate in A.G.P’s Virtual Technology Conference
--News Direct-- 
Via News Direct
Topics Regulatory Compliance
Exposures Legal Regulatory
Foresight to Participate in A.G.P’s Virtual Technology Conference
Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“FRSX” or the “Company”), an innovator in automotive vision systems, today announced that management will participate in the Alliance Global... 
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
RBC Capital Maintains Outperform Rating for Popular: Here's What You Need To Know
Via Benzinga
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says
Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.